Learn about the MLR assay and why it is an essential component of the compound screening pipeline for drug development.
29 result(s)
Large-scale gain-of-function screens have not yet shown the same popularity as loss-of function experiments, mainly due to logistical complications of using the traditional reagents (ORFs). Here we explain the hurdles to setting up a high-throughput ORF screen, and how CRISPRa offers a new solution that can expand the screening toolbox to maximize your window of discovery.
Learn about Horizon's CRISPRsc (CRISPR single cell) platform that combines the flexibility of pooled screening with the power of transcriptomics at single cell resolution.
A review of two studies demonstrating that large-scale pooled base editor screens can separate pathogenic from benign mutations and identify variants that are associated with altered cellular growth or response to DNA-damaging agents.
A summary of a recent publication in The Journal of Biotechniques showing the utility of Horizon's synthetic sgRNA for CRISPR mediated transcriptional activation studies.
Here we discuss a recent paper by Gisela Jimenez-Duran and colleagues highlighting how a whole genome CRISPR knockout screen, carried out by Horizon Discovery, has enabled identification of a pre-existing inhibitor that can regulate pro-inflammatory macrophages.
Thinking about doing CRISPR screening for knock out, CRISPR activation or CRISPRi applications? Unsure whether a synthetic arrayed or pooled lentiviral screening library is best for your project? We are here to help.
A summary of a recent publication in The CRISPR Journal showing that Horizon's integrated pooled CRISPRko and high throughput cell panel screening platform together offer clinically relevant information for therapeutic targets.
Here we talk about the role of the Edit-R Pooled sgRNA Indexing PCR Primers and answer the most common questions about the Indexing PCR and Sequencing Primer kit.
Demonstration of a repeatable pooled lentiviral sgRNA screen in primary human T cells